Hologic (FRA:HO1) Current Deferred Revenue: €146 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HO1 Hologic Inc FRA:HO1
57 GF Score
Price €65.00
GF Value €70.17
! 5 Warning Signs
View Full Analysis

What is Hologic Current Deferred Revenue?

Hologic FRA:HO1 57 Current Deferred Revenue is €146 Mil as of Dec. 2025. GuruFocus rates FRA:HO1 with a GF Score™ of 57/100 and a GF Value™ of €70.17. The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Hologic's current deferred revenue for the quarter that ended in Dec. 2025 was €146 Mil.

Hologic Current Deferred Revenue Related Terms

Hologic Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Hologic's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic Current Deferred Revenue Chart

Hologic Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.30 188.37 186.65 191.82 170.14

Hologic Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.06 197.30 184.41 170.14 145.95
FRA:HO1
57GF Score
Hologic Inc FRA:HO1
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €146 Mil mean?
Hologic (FRA:HO1) has a Current Deferred Revenue of €146 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Hologic and its competitors.
Is Hologic's Current Deferred Revenue too high?
Hologic's current Current Deferred Revenue is €146 Mil. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Current Deferred Revenue compare to WST and COO?
Hologic's Current Deferred Revenue of €146 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Hologic and its competitors. Hologic's current Current Deferred Revenue is €146 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current Current Deferred Revenue of €146 Mil. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current Current Deferred Revenue is €146 Mil. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Hologic (FRA:HO1), the current Current Deferred Revenue is €146 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hologic (FRA:HO1) Overvalued in 2026?

Based on GuruFocus' analysis, Hologic stock appears to be undervalued. The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.

Key valuation signals for FRA:HO1:

  • Current Deferred Revenue: €146 Mil
  • GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hologic Business Description

Address 250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score

Get the complete analysis for FRA:HO1

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€70.17
GF Value